-
| ISIN | US92765F1084 |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | -0.29 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 15.4 |
| PE Ratio | None |
| Market Cap | 56M |
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February, 2021. The company was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VIRX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024